• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Type 1 Diabetes Market 2014-2018 - Product Image

Global Type 1 Diabetes Market 2014-2018

  • Published: May 2014
  • Region: Global
  • 85 pages
  • TechNavio


  • Astrazeneca plc
  • Diamyd Medical AB
  • Eli Lilly and Co.
  • MannKind Corp.
  • Osiris Therapeutics Inc.
  • Tolerion Inc.
  • MORE

About Type 1 Diabetes

Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against self-insulin producing cells. This, in turn, hampers the body’s ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes T1D differs from the more common form of diabetes mellitus, Type 2 diabetes, as people with Type 2 diabetes do produce insulin. T1D accounts for only 5-15 percent of the total diabetic cases and is usually reported in children and adolescents. T1D was formerly known as juvenile diabetes. T1D management relies on providing symptomatic relief and improving quality of life.
The analysts forecast the Global Type 1 Diabetes Market will grow at a CAGR of 6.9 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Type 1 Diabetes Market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of various type 1 diabetes management drugs, which includes insulin-based replacement products and amylin analogues.

The report, READ MORE >

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Global Market Share by Products
08. Product Portfolio
09. Clinical Pipeline Portpolio
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
18.1 Competitive Scenario
18.1.1 Key News
18.1.2 Mergers and Acquisitions
18.2 Market Share Analysis 2013
18.3 Future Vendors Expected to Tap the Market

List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Type 1 Diabetes Drugs Market 2013-2018 (US$ million)
Exhibit 3: Global Market Share of Diabetes Drugs 2013 (US$ million)
Exhibit 4: Global Type 1 Diabetes Market by Geographical Segmentation 2013
Exhibit 5: Incidence and Prevalence of Type1 Diabetes in Children (0-14 Years) 2013 (in thousands)
Exhibit 6: Market Share of Vendors in Global Type 1 Diabetes Market (in Percent)
Exhibit 7: Revenue Share of Novo Nordisk’s Insulin Products (in Percent)
Exhibit 8: Novo Nordisk’s Insulin Products Revenue Segmentation by Geography (in Percentage)
Exhibit 9: Geography Wise Revenue of Novo Nordisk’s Insulin Products (US$ million)
Exhibit 10: Eli Lilly’s Insulin Products Revenue Segmentation by Geography (in Percentage)
Exhibit 11: Geography Wise Revenue of Eli Lilly’s Insulin Products (US$ million)
Exhibit 12: Sanofi’s Insulin Products Revenue Segmentation by Geography (in Percentage)

Commenting on the report, an analyst from the team said: “The key vendors in the Global Type 1 Diabetes market are increasing their penetration in the emerging markets. Recent years have witnessed an increase in investment in manufacturing sites based in these countries with the intention to enhance the production of drugs such as insulin for local or global markets. For instance, the Frankfurt site is a key manufacturer for Sanofi diabetes products. However, Sanofi has invested in Russia for its Orel-based site to enable the production of insulin prefilled devices. For a similar category of products, Sanofi has also invested in a manufacturing site in Beijing to penetrate the market. Recently, Sanofi transferred the manufacturing technologies for Insuman insulin to Shantha Biotech in India (part of the Sanofi group). In 2009, Novo Nordisk completely transferred the production of NovoPen from Denmark to Tianjin. Also, in 2008, Novo Nordisk started the construction of an advanced insulin filling plant in Tianjin, which is expected to cater to the demand of the Chinese market for Penfill, the insulin based solution for injection in cartridges.”

According to the report, one of the main drivers in this market is the increase in the global type 1 diabetic population. The global type 1 diabetes population is increasing every year with an annual increase of 3 percent in children below 14 years of age. An increase in the type 1 diabetic population might increase the number of people opting for treatment. This will drive the sale and revenue of these drugs.

Further, the report states that one of the major challenges is the side effects of current therapies for type 1 diabetes. A lack of effective treatment that can manage glucose levels without causing adverse effects considerably decreases effective disease management.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

- Astrazeneca plc
- Eli Lilly and Co.
- Novo Nordisk A/S
- Sanofi-Aventis US LLC
- Biodel Inc.
- Diamyd Medical AB
- DiaVacs Inc.
- Generex Biotechnology Corp.
- Lexicon Pharmaceuticals Inc.
- Macrogenics Inc.
- MannKind Corp.
- Osiris Therapeutics Inc.
- Tolerion Inc.
- XOMA Corp.

Note: Product cover images may vary from those shown


Our Clients

Our clients' logos